glp 1 aafp Benefits and Risks of GLP-1 Receptor Agonists Outlined Pharmacotherapy - Obesity Management Glucagon-Like Peptide-1 Based Therapies: A

Its primary actions include: Inhibiting the reuptake of dopamine and noradrenaline in the central nervous system Minimal effect on serotonin pathways, distinguishing it from most other antidepressants Potential appetite suppression as a secondary effect, though this is not its primary indication Reducing nicotine cravings through dopaminergic pathways Bupropion is metabolised primarily in the liver by the CYP2B6 enzyme system, producing active metabolites

R., Nierenberg, A

The obesity rate in adolescents has quadrupled over the last 30 years

[17] The G6PD / NADPH pathway is the only source of reduced glutathione in red blood cells (erythrocytes)

It presents this as a difference in mechanism rather than a promise of better results, noting response rates vary considerably between individuals